Straits Times Index
3,296.39 +23.67 (+0.72%) Nikkei
38,329.39 +777.23 (+2.07%) Hang Seng
17,126.24 +297.31 (+1.77%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,649.02 -129.31 (-0.19%) CMC Crypto 200
1,433.79 +19.03 (+1.34%)
SK Inc. (034730.KS)
| Previous close | 160,700.00 |
| Open | 162,500.00 |
| Bid | 162,200.00 x 0 |
| Ask | 162,300.00 x 0 |
| Day's range | 161,700.00 - 164,200.00 |
| 52-week range | 134,700.00 - 212,000.00 |
| Volume | |
| Avg. volume | 211,675 |
| Market cap | 8.849T |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | 5,000.00 (3.11%) |
| Ex-dividend date | 29 Mar 2024 |
| 1y target est | 250,000.00 |
PR NewswireSK E&S, strengthening 'Low-Carbon Hydrogen Partnership' at COP28... accelerating global carbon neutrality
SK E&S has collaborated with global partners to establish foundation for the domestic low-carbon hydrogen* industry, with support from local government. They plan to mass-produce low-carbon hydrogen, leading the early establishment of the domestic hydrogen ecosystem and contributing to global carbon neutrality.
- Reuters SG
UPDATE 2-Vietnam's Masan expects to unveil exit pact with Korea's SK soon
Vietnamese conglomerate Masan expects to announce a pact soon with South Korean partner SK for the latter's exit from their partnership, the chief executive said on Monday, adding that the process could take years. Shares of the leader in Vietnam's food processing industry fell last Friday to 57,800 dong ($2.36) each, their lowest since late 2020, on rumours of a possible $500-million cash outflow from SK's investment in Masan, brokers and traders have said. Masan's Chief Executive Danny Le denied the rumours, telling analysts and investors that Masan would announce the agreement in the next couple of days.
PR NewswireSK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023
SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities.
